From Co-Stimulation to Co-Inhibition: A Continuum of Immunotherapy Care Toward Long-Term Survival in Melanoma

References

• Hamid O, Robert C, Daud A, et al. Five-year survival outcomes for patients with advanced melanoma treated with pembrolizumab in KEYNOTE-001. Ann Oncol. 2019;30(4):582–588. doi:10.1093/annonc/mdz011
   PubMed Web of Science ®Google Scholar
• Robert C, Long GV, Brady B, et al. Five-year outcomes with nivolumab in patients with wild -type. J Clin Oncol. 2020;38(33):3937–3946. doi:10.1200/JCO.20.00995
   PubMed Web of Science ®Google Scholar
• Maio M, Di Giacomo AM, Robert C, Eggermont AM. Update on the role of ipilimumab in melanoma and first data on new combination therapies. Curr Opin Oncol. 2013;25(2):166–172. doi:10.1097/CCO.0b013e32835dae4f
   PubMed Web of Science ®Google Scholar
• Hodi FS, O’Day SJ, McDermott DF, et al. Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med. 2010;363(8):711–723. doi:10.1056/NEJMoa1003466
   PubMed Web of Science ®Google Scholar
• Maio M, Grob JJ, Aamdal S, et al. Five-year survival rates for treatment-naive patients with advanced melanoma who received ipilimumab plus dacarbazine in a phase III trial. J Clin Oncol. 2015;33(10):1191–1196. doi:10.1200/JCO.2014.56.6018
   PubMed Web of Science ®Google Scholar
• Schadendorf D, Hodi FS, Robert C, et al. Pooled analysis of long-term survival data from Phase II and phase III trials of ipilimumab in unresectable or metastatic melanoma. J Clin Oncol. 2015;33(17):1889–1894. doi:10.1200/JCO.2014.56.2736
   PubMed Web of Science ®Google Scholar
• Wolchok JD, Chiarion-Sileni V, Gonzalez R, et al. Long-term outcomes with nivolumab plus ipilimumab or nivolumab alone versus ipilimumab in patients with advanced melanoma. J Clin Oncol. 2022;40(2):127–137. doi:10.1200/JCO.21.02229
   PubMed Web of Science ®Google Scholar
• Chen X, Zhang W, Yang W, Zhou M, Liu F. Acquired resistance for immune checkpoint inhibitors in cancer immunotherapy: challenges and prospects. Aging. 2022;14(2):1048–1064. doi:10.18632/aging.203833
   PubMedGoogle Scholar
• Melero I, Hirschhorn-Cymerman D, Morales-Kastresana A, Sanmamed MF, Wolchok JD. Agonist antibodies to TNFR molecules that costimulate T and NK cells. Clin Cancer Res. 2013;19(5):1044–1053. doi:10.1158/1078-0432.CCR-12-2065
   PubMed Web of Science ®Google Scholar
• Chester C, Ambulkar S, Kohrt HE. 4-1BB agonism: adding the accelerator to cancer immunotherapy. Cancer Immunol Immunother. 2016;65(10):1243–1248. doi:10.1007/s00262-016-1829-2
   PubMed Web of Science ®Google Scholar
• Sanmamed MF, Pastor F, Rodriguez A, et al. Agonists of co-stimulation in cancer immunotherapy directed against CD137, OX40, GITR, CD27, CD28, and ICOS. Semin Oncol. 2015;42(4):640–655. doi:10.1053/j.seminoncol.2015.05.014
   PubMed Web of Science ®Google Scholar
• Marinelli O, Nabissi M, Morelli MB, et al. ICOS-L as a potential therapeutic target for cancer immunotherapy. Curr Protein Pept Sci. 2018;19(11):1107–1113. doi:10.2174/1389203719666180608093913
   PubMed Web of Science ®Google Scholar
• Fan X, Quezada SA, Sepulveda MA, et al. Engagement of the ICOS pathway markedly enhances efficacy of CTLA-4 blockade in cancer immunotherapy. J Exp Med. 2014;211(4):715–725. doi:10.1084/jem.20130590
   PubMed Web of Science ®Google Scholar
• Burris HA, Callahan MK, Tolcher AW, et al. Phase 1 safety of ICOS agonist antibody JTX-2011 alone and with nivolumab (nivo) in advanced solid tumors; predicted vs observed pharmacokinetics (pK) in iconic. J Clin Oncol. 2017;35(15 Suppl):3033. doi:10.1200/JCO.2017.35.15_suppl.3033
   Google Scholar
• Yap TA, Gainor JF, Callahan MK, et al. First-in-human Phase I/II ICONIC trial of the ICOS agonist vopratelimab alone and with nivolumab: ICOS-High CD4 T-cell populations and predictors of response. Clin Cancer Res. 2022;28(17):3695–3708. doi:10.1158/1078-0432.CCR-21-4256
   PubMed Web of Science ®Google Scholar
• Jounce Therapeutics. Jounce therapeutics announces update on vopratelimab program; 2020. Available from: https://ir.jouncetx.com/news-releases/news-release-details/jounce-therapeutics-announces-update-vopratelimab-program/. Accessed November 6, 2022.
   Google Scholar
• Maio M, Weber JS, Villar MV, et al. Inducible T cell costimulatory (ICOS) receptor agonist, feladilimab (FE), alone and in combination (combo) with pembrolizumab (PE): results from INDUCE-1 relapsed/refractory (R/R) melanoma expansion cohorts (EC). Cancer Res. 2021;81(13 Suppl):CT033. doi:10.1158/1538-7445.AM2021-CT033
   Web of Science ®Google Scholar
• GlaxoSmithKline. GSK provides update on feladilimab, an investigational inducible T cell co-stimulatory (ICOS) agonist; 2021. Available from: www.gsk.com/en-gb/media/press-releases/gsk-provides-update-on-feladilimab-an-investigational-inducible-t-cell-co-stimulatory-icos-agonist/. Accessed November 6, 2022.
   Google Scholar
• Solinas C, Gu-Trantien C, Willard-Gallo K. The rationale behind targeting the ICOS-ICOS ligand costimulatory pathway in cancer immunotherapy. ESMO Open. 2020;5(1):e000544. doi:10.1136/esmoopen-2019-000544
   PubMed Web of Science ®Google Scholar
• Segal NH, Logan TF, Hodi FS, et al. Results from an integrated safety analysis of urelumab, an agonist anti-CD137 monoclonal antibody. Clin Cancer Res. 2017;23(8):1929–1936. doi:10.1158/1078-0432.CCR-16-1272
   PubMed Web of Science ®Google Scholar
• Segal NH, He AR, Doi T, et al. Phase 1 study of single agent utolimumab PF-05082566, an anti-4-1BB/cd137 agonist in patients with advanced cancer. Clin Cancer Res. 2018;24(8):1816–1823. doi:10.1158/1078-0432.CCR-17-1922
   PubMed Web of Science ®Google Scholar
• Tolcher AW, Sznol M, Hu-Lieskovan S, et al. Phase Ib study of Utolimumab (PF-05082566), a 4-1BB/CD137 Agonist, in combination with pembrolizumab (MK-3475) in patients with advanced solid tumors. Clin Cancer Res. 2017;23(18):5349–5357. doi:10.1158/1078-0432.CCR-17-1243
   PubMed Web of Science ®Google Scholar
• Curran MA, Kim M, Montalvo W, Al-Shamkhani A, Allison JP, von Herrath MG. Combination CTLA-4 blockade and 4-1BB activation enhances tumor rejection by increasing T-cell infiltration, proliferation, and cytokine production. PLoS One. 2011;6(4):e19499. doi:10.1371/journal.pone.0019499
   PubMed Web of Science ®Google Scholar
• Ji RR, Chasalow SD, Wang L, et al. An immune-active tumor microenvironment favors clinical response to ipilimumab. Cancer Immunol Immunother. 2012;61(7):1019–1031. doi:10.1007/s00262-011-1172-6
   PubMed Web of Science ®Google Scholar
• Taube JM, Young GD, Mc Miller TL, et al. Differential expression of immune-regulatory genes associated with PD-L1 display in melanoma: implications for PD-1 pathway blockade. Clin Cancer Res. 2015;21(17):3969–3976. doi:10.1158/1078-0432.CCR-15-0244
   PubMed Web of Science ®Google Scholar